Cargando…
Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility
The race among countries and companies to develop efficacious vaccines and therapeutics for the COVID-19 is ongoing fast, with many trials underway. Among this, cell-based therapy is focused on moderate to severe phases of COVID-19, and there have been promising outcomes. Mesenchymal stem cells (MSC...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532742/ https://www.ncbi.nlm.nih.gov/pubmed/33009982 http://dx.doi.org/10.1007/s12015-020-10046-1 |